Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112,341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration.
Guo F, Liu B, Li X, Wang H, Zhu X, Su Y, He C, Zhu M, Ding J, Xu Y, Zhao X, Wang Y, Shan R, Zhu J, Xie J, Ge Q, Fan L, Ding Y, Xie Y, Zhang C, Li H, Wang H, Zhou H. Guo F, et al. Among authors: li x, li h. Cancer Chemother Pharmacol. 2023 Feb;91(2):143-156. doi: 10.1007/s00280-022-04493-5. Epub 2022 Dec 27. Cancer Chemother Pharmacol. 2023. PMID: 36572783
A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer.
Li Y, Qi L, Wang Y, Li Y, Lei C, Zhang Y, Cheng X, Liu J, Bai H, Zhao X, Lv S, Xiong B, Liu J, Shi Y, Zhou H, Li H, Liu L, Jiang H, Ouyang W, Li X, Li Y, Wang X. Li Y, et al. Among authors: li h, li x. Front Oncol. 2022 Dec 20;12:1070001. doi: 10.3389/fonc.2022.1070001. eCollection 2022. Front Oncol. 2022. PMID: 36605440 Free PMC article.
A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin® in healthy Chinese male subjects.
Li H, Zhao X, Xie J, Zhu X, Su Y, He C, Ding J, Zhu M, Xu Y, Wang Y, Shan R, Liu B, Ding Y, Liu Y, Zhou H, Xie Y. Li H, et al. BMC Pharmacol Toxicol. 2023 May 27;24(1):36. doi: 10.1186/s40360-023-00673-y. BMC Pharmacol Toxicol. 2023. PMID: 37245022 Free PMC article. Clinical Trial.
Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor.
Li H, Shan R, Ding J, Zhang J, Liu B, Ge Q, Cheng D, Li L, Zhang C, Su H, Li X, Li H, Ye J, Li H, Li F, Zhou H, Huo Q, Su Y. Li H, et al. Among authors: li f, li x, li l. Expert Opin Drug Metab Toxicol. 2023 Dec;19(12):1015-1021. doi: 10.1080/17425255.2023.2292735. Epub 2024 Jan 12. Expert Opin Drug Metab Toxicol. 2023. PMID: 38059472 Clinical Trial.
112,341 results
You have reached the last available page of results. Please see the User Guide for more information.